Keratopathy of patients with aniridia leads to epithelial scarring disorders and a progressive clouding of the cornea linked to this abnormal healing (fibrosis). Treatment with autologous serum is usually undertaken to promote epithelial healing.
However, autologous serum does not prevent the formation of fibrosis, whereas growth factor-rich plasma appears to be associated with a reduction in the in vitro expression of fibrosis markers. This study seeks to compare the in vitro healing and anti-fibrotic properties of autologous serum and growth factor rich plasma from aniridia patients and healthy controls.
With aniridia
Patient weighing more than 43 kg
If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection
If a blood donation has been made, a delay of 8 weeks must be respected after the last donation
Insufficient sample volume
No conjunctival print
HBV, HCV, HIV serology positive
Aniridia not genetically confirmed for cases For each patient excluded, a new patient will be included in order to maintain the number of patients required for data analysis.